The Russian government adopted the action plan (roadmap) for the Development of Biotechnology and Genetic Engineering in 2018 – 2020.
The plan aims at developing domestic demand, manufacturing and exports of biotech products, and building institutional environment in order to modernize the technology base of the industry through mass introduction of biotech methods and products.
It provides for further expansion of production potential and cooperation in the area of biomedicine and biopharmaceuticals, agricultural and industrial biotechnology, bioenergetics, forest and environmental biotechnology, and genetic engineering.
By 2020, 2 common use production centers licensed for manufacturing biomedical cell products will be established to conduct R&D and pre-clinical studies of biomedical cell products.
The number of medical institutions accredited for clinical trials of biomedical cell products will be increased from 5 to 50.
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.